Michael Bscheider

Michael Bscheider

Auto-generated profile, based on publicly available information

Michael Bscheider

Roche Pharma Research & Early Development Roche Innovation Center Basel Basel Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2017 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
JFJulius Clemens Fischer
Julius Clemens Fischer
MBMichael Bscheider
Michael Bscheider
GEGabriel Eisenkolb
Gabriel Eisenkolb
CLChia-Ching Lin
Chia-Ching Lin
AWAlexander Wintges
Alexander Wintges
HPHendrik Poeck
Hendrik Poeck
Activation of the RIG-I or STING pathways results in a type I interferon response that protects gut integrity after irradiation- or immune-induced tissue injury.

6 September 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RJRaphaël Jeger-Madiot
Raphaël Jeger-Madiot
DPDelphine Planas
Delphine Planas
ISIsabelle Staropoli
Isabelle Staropoli
HDHippolyte Debarnot
Hippolyte Debarnot
JKJérômE Kervevan
JérômE Kervevan
LClisa chakrabarti
lisa chakrabarti
Predicting the immunogenicity of candidate vaccines in humans remains a challenge. To address this issue, we developed a lymphoid organ-chip (LO chip) model based on a microfluidic chip seeded with human PBMC at high density within a 3D collagen matrix. Perfusion of the SARS-CoV-2 spike protein mimicked a vaccine boost by inducing a massive amplification of spike-specific memory B cells, plasmablast differentiation, and spike-specific antibody secretion. Features of lymphoid tissue, including the formation of activated CD4+ T cell/B cell clusters and the emigration of matured plasmablasts, were recapitulated in the LO chip. Importantly, myeloid cells were competent at capturing and expressing mRNA vectored by lipid nanoparticles, enabling the assessment of responses to mRNA vaccines. Comparison of on-chip responses to Wuhan monovalent and Wuhan/Omicron bivalent mRNA vaccine boosts showed equivalent induction of Omicron neutralizing antibodies, pointing at immune imprinting as reported in vivo. The LO chip thus represents a versatile platform suited to the preclinical evaluation of vaccine-boosting strategies.

23 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
AVAlberto Valdeolivas
Alberto Valdeolivas
BABettina Amberg
Bettina Amberg
NGNicolas Giroud
Nicolas Giroud
MRMarion Richardson
Marion Richardson
EGEric J.C. Gálvez
Eric J.C. Gálvez
KHKerstin Hahn
Kerstin Hahn
The heterogeneity of colorectal cancer (CRC) contributes to substantial differences in patient response to standard therapies. The consensus molecular subtypes (CMS) of CRC is the most widely-used gene expression-based classification and has contributed to a better understanding of disease heterogeneity and prognosis. Nevertheless, CMS intratumoral heterogeneity restricts its clinical application, stressing the necessity of further characterizing the composition and architecture of CRC. Here, we used Spatial Transcriptomics (ST) in combination with single-cell RNA sequencing (scRNA-seq) to decipher the spatially resolved cellular and molecular composition of CRC. In addition to mapping the intratumoral heterogeneity of CMS and their microenvironment, we identified cell communication events in the tumor-stroma interface of CMS2 carcinomas. This includes tumor growth-inhibiting as well as -activating signatures, such as the potential regulation of the ETV4 transcriptional activity by DCN or the PLAU-PLAUR ligand-receptor interaction. Our data show the power of ST to bring the CMS-based classification of CRC to another level and thereby gain useful molecular insights for personalized therapy.

3 December 2015 in Blood
Verified
Journal Article
Open access
SHSimon Heidegger
Simon Heidegger
DKDiana Kreppel
Diana Kreppel
MBMichael Bscheider
Michael Bscheider
AWAlexander Wintges
Alexander Wintges
SBSarah Bek
Sarah Bek
HPHendrik Poeck
Hendrik Poeck
Antibody-mediated targeting of regulatory T cell receptors such as CTLA-4 has been shown to enhance anti-tumor immune responses against several cancer entities including malignant melanoma. Yet, therapeutic success in patients remains variable underscoring the need for novel combinatorial approaches. Here we established a vaccination protocol that combines selective engagement of the nucleic acid-sensing pattern recognition receptor RIG-I, antigen and CTLA-4-blockade. We found that vaccination together with RIG-I ligation strongly synergized with CTLA-4 blockade to induce expansion and activation of antigen-specific CD8+ T cells and potent anti-tumor immunity. Cross-priming of cytotoxic T cells as well as anti-tumor immunity required the adapter protein MAVS and type I interferon (IFN) signaling and were mediated by dendritic cells. In addition, the benefit of the combined immunization with anti-CTLA-4 was reduced by systemic antibiotics pointing to the requisite of an intact commensal microbiota in this context. Together, our findings describe a novel combinatorial strategy that may form the basis for the design of new type I IFN-based regimens that enhance antigen-specific T cell reactivity against cancer.

1 June 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
DDDenis Dermadi
Denis Dermadi
MBMichael Bscheider
Michael Bscheider
KBKristina Bjegovic
Kristina Bjegovic
NLNicole H. Lazarus
Nicole H. Lazarus
ASAgata Szade
Agata Szade
EBEugene C. Butcher
Eugene C. Butcher
High-dimensional single cell profiling coupled with computational modeling is emerging as a powerful means to elucidate developmental sequences and define genetic programs directing cell lineages. Here we introduce tSpace, an algorithm based on the concept of “trajectory space”, in which cells are defined by their distance along nearest neighbor pathways to every other cell in a population. tSpace outputs a dense matrix of cell-to-cell distances that quantitatively reflect the extent of phenotypic change along developmental paths (developmental distances). Graphical mapping of cells in trajectory space allows unsupervised reconstruction and straightforward exploration of complex developmental sequences. tSpace is robust, scalable, and implements a global approach that attempts to preserve both local and distant relationships in developmental pathways. Applied to high dimensional flow and mass cytometry data, the method faithfully reconstructs known pathways of thymic T cell development and provides novel insights into regulation of tonsillar B cell development and trafficking. Applied to single cell transcriptomic data, the method unfolds complex developmental sequences, recapitulates pathways leading from intestinal stem cells to specialized epithelial phenotypes more faithfully than existing algorithms, and reveals genetic programs that correlate with fate decisions. tSpace profiling of complex populations in high-dimensional trajectory space is well suited for hypothesis generation in developing cell systems.

17 June 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
TKThomas E. Kraft
Thomas E. Kraft
EMEstelle Marrer‐Berger
Estelle Marrer‐Berger
SBSara Belli
Sara Belli
HHHelene Haegel
Helene Haegel
ASAnneliese Schneider
Anneliese Schneider
TFTanja Fauti
Tanja Fauti
The minimal anticipated biological effect level (MABEL) approach to first‐in‐human (FIH) dose calculation can lead to long dose‐escalation periods before observing clinical activity. We used a novel ex vivo MABEL approach to calculate the FIH starting dose for forimtamig, a T‐cell bispecific antibody under investigation for the treatment of relapsed/refractory multiple myeloma (RRMM). We used in vitro and ex vivo MABEL approaches to calculate the FIH dose for a Phase 1 trial (NCT04557150) in patients with RRMM. In vitro assays used the OPM‐2 MM cell line and peripheral blood mononucleocytes from healthy donors and patients with MM. Ex vivo assays used fresh bone marrow aspirates from MM patient donors. Forimtamig increased tumor cell lysis, cytokine release, and T‐cell activation in vitro and ex vivo . Tumor cell lysis was considered the most relevant assay for dose calculation. EC 50 for LDH release ( in vitro : mean 0.6 pM; ex vivo : 9 pM for the most sensitive patient) led to calculated FIH starting doses of 0.4 and 6 μg, respectively. FIH starting dose was 6 μg. Clinical activity was observed in the second dosing cohort (18 and 54 μg). The third dosing cohort (54 and 162 μg) showed durable objective responses. Cytokine release syndrome was Grade 1 at the starting dose and absent in the second dosing cohort. Our ex vivo MABEL approach was accepted by regulatory authorities and yielded a tolerated forimtamig FIH starting dose which demonstrated clinical activity in the second dosing cohort. We encourage similar innovative patient‐centric approaches to FIH dose calculation.